{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:34:28Z","timestamp":1794108868143,"version":"4.8.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Medetomidine, a potent \u03b12-adrenergic agonist, is an emerging contaminant in the US illicit opioid supply. It is a racemic mixture that includes the sedative dexmedetomidine and can lead to severe and complicated withdrawal symptoms requiring novel management strategies. In this therapy update, we provide insights on the identification and management of medetomidine withdrawal based on our clinical experiences with it over the past year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Medetomidine withdrawal can occur precipitously, typically 4 to 6\u2005hours after last use in regular users, and lead to severe symptoms and complications including agitation, tremors, and widespread sympathetic activation. Prompt identification of withdrawal is vital to initiate oral and transdermal \u03b12-agonist therapy, often at doses higher than those required for labeled indications. Severe nausea and vomiting are typically present and may be refractory to standard treatments and prevent oral therapies from being administered. Intravenous dexmedetomidine is recommended for those for whom oral \u03b12-agonist therapy is ineffective or who are unable to tolerate enteral therapies. This may require aggressive dose titration and infusion rates that are above those in typical sedation protocols. In addition to \u03b12 withdrawal, patients may have withdrawal from concomitant opioids, benzodiazepines, or other substances that requires additional treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Medetomidine withdrawal can lead to severe hemodynamic and autonomic complications that require a multimodal treatment strategy. Clinicians should be familiar with the signs, symptoms, and timing of medetomidine withdrawal along with the complex management that is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag141","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:00:49Z","timestamp":1777842049000},"source":"Crossref","is-referenced-by-count":7,"title":["Presentation and management of acute medetomidine withdrawal"],"prefix":"10.1093","author":[{"given":"David E","family":"Zimmerman","sequence":"first","affiliation":[{"name":"Duquesne University School of Pharmacy , Pittsburgh, PA"},{"name":"University of Pittsburgh Medical Center\u2013Mercy Hospital , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Goodstein","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Hospital , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Philip A","family":"Durney","sequence":"additional","affiliation":[{"name":"Jefferson Addiction Multidisciplinary Service , Philadelphia, PA"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal H","family":"Patel-Francis","sequence":"additional","affiliation":[{"name":"Jefferson Health, Center City Campus , Philadelphia, PA"},{"name":"Jefferson Methodist Hospital , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kory S","family":"London","sequence":"additional","affiliation":[{"name":"Jefferson Addiction Multidisciplinary Service , Philadelphia, PA"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"30","key":"2026060813064810400_zxag141-B1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.15585\/mmwr.mm7330a3","article-title":"; Toxicology Investigators Consortium Fentalog Study Group. Notes from the field: detection of medetomidine among patients evaluated in emergency departments for suspected opioid overdoses\u2013Missouri, Colorado, and Pennsylvania, September 2020\u2013December 2023","volume":"73","author":"Schwarz","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2026060813064810400_zxag141-B2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/15563650.2025.2500601","article-title":"Clinical characteristics of patients exposed to medetomidine in the illicit opioid drug supply in Philadelphia\u2014a case series","volume":"63","author":"Murphy","year":"2025","journal-title":"Clin Toxicol"},{"issue":"15","key":"2026060813064810400_zxag141-B3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.15585\/mmwr.mm7415a2","article-title":"Notes from the field: suspected medetomidine withdrawal syndrome among fentanyl-exposed patients\u2013Philadelphia, Pennsylvania, September 2024\u2013January 2025","volume":"74","author":"Huo","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026060813064810400_zxag141-B4","author":"Philadelphia Department of Public Health"},{"issue":"21","key":"2026060813064810400_zxag141-B5","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1021\/acschemneuro.4c00583","article-title":"Classics in chemical neuroscience: medetomidine","volume":"15","author":"Horn","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"2026060813064810400_zxag141-B6","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1124\/dmd.108.021709","article-title":"Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes","volume":"36","author":"Kaivosaari","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"2026060813064810400_zxag141-B7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2885.1998.00113.x","article-title":"Affinity of detomidine, medetomidine and xylazine for \u03b12 adrenergic receptor subtypes","volume":"21","author":"Schwartz","year":"1998","journal-title":"J Vet Pharmacol Ther"},{"issue":"1-2","key":"2026060813064810400_zxag141-B8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(88)90744-3","article-title":"Characterization of the selectivity, specificity and potency of medetomidine as an \u03b12-adrenoceptor agonist","volume":"150","author":"Virtanen","year":"1988","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"2026060813064810400_zxag141-B9","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.7326\/M23-2001","article-title":"Xylazine adulteration of the heroin-fentanyl drug supply: a narrative review","volume":"176","author":"D\u2019Orazio","year":"2023","journal-title":"Ann Intern Med"},{"issue":"4","key":"2026060813064810400_zxag141-B10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2125.1987.tb03196.x","article-title":"Sedative and cardiovascular effects of medetomidine, a novel selective \u03b12 adrenoceptor agonist, in healthy volunteers","volume":"24","author":"Scheinin","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"2026060813064810400_zxag141-B11","first-page":"145","article-title":"Pharmacological effects of medetomidine in humans","volume":"85","author":"Scheinin","year":"1989","journal-title":"Acta Vet Scand Suppl"},{"issue":"5","key":"2026060813064810400_zxag141-B12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0278-5846(89)90051-1","article-title":"Medetomidine\u2014a novel \u03b12 adrenoceptor agonist: a review of its pharmacodynamic effects","volume":"13","author":"Scheinin","year":"1989","journal-title":"Prog Neurpsychopharmacol Biol Psychiatry"},{"key":"2026060813064810400_zxag141-B13","first-page":"49","article-title":"Pharmacokinetics of medetomidine","volume":"85","author":"Salonen","year":"1989","journal-title":"Acta Vet Scand Suppl"},{"key":"2026060813064810400_zxag141-B14"},{"key":"2026060813064810400_zxag141-B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/biomed5020013","article-title":"Decreased effectiveness of a novel opioid withdrawal protocol following the emergence of medetomidine as a fentanyl adulterant","volume":"5","author":"London","year":"2025","journal-title":"BioMed"},{"key":"2026060813064810400_zxag141-B16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajem.2024.08.036","article-title":"Tranq dope: characterization of an ED cohort treated with a novel opioid withdrawal protocol in the era of fentanyl\/xylazine","volume":"85","author":"London","year":"2024","journal-title":"Am J Emerg Med"},{"issue":"14","key":"2026060813064810400_zxag141-B17","doi-asserted-by":"publisher","first-page":"6715","DOI":"10.3390\/ijms26146715","article-title":"Biochemical identification and clinical description of medetomidine exposure in people who use fentanyl in Philadelphia, PA","volume":"26","author":"Durney","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026060813064810400_zxag141-B18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/ADM.0000000000001560","article-title":"Severe fentanyl withdrawal associated with medetomidine adulteration: a multicenter study from Philadelphia, PA","volume":"20","author":"London","year":"2026","journal-title":"J Addict Med"},{"issue":"1","key":"2026060813064810400_zxag141-B19","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1097\/PCC.0000000000003645","article-title":"Development and preliminary testing of the withdrawal assessment tool\u2013\u03b12 agonist: an assessment instrument for monitoring iatrogenic withdrawal symptoms in children receiving an \u03b12 agonist","volume":"26","author":"Solodiuk","year":"2025","journal-title":"Pediatr Crit Care Med"},{"issue":"5","key":"2026060813064810400_zxag141-B20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/ajad.70030","article-title":"Rise of illicit medetomidine use: a worrisome trend","volume":"34","author":"Sood","year":"2025","journal-title":"Am J Addict"},{"key":"2026060813064810400_zxag141-B21"},{"issue":"4","key":"2026060813064810400_zxag141-B22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/psychoactives4040037","article-title":"Profound opioid and medetomidine withdrawal: a case series and narrative review of available literature","volume":"4","author":"Durney","year":"2025","journal-title":"Psychoactives"},{"key":"2026060813064810400_zxag141-B23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/00185787211029552","article-title":"High versus standard dose dexmedetomidine in critically ill patients: a randomized controlled trial","volume":"43","author":"Kobayashi","year":"2015","journal-title":"Crit Care Med"},{"key":"2026060813064810400_zxag141-B24","first-page":"42","article-title":"Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology","author":"Tobias","year":"2011","journal-title":"Open Anesth J"},{"issue":"5","key":"2026060813064810400_zxag141-B25","doi-asserted-by":"publisher","first-page":"R257","DOI":"10.1186\/cc10518","article-title":"Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients","volume":"15","author":"Iirola","year":"2011","journal-title":"Crit Care"},{"key":"2026060813064810400_zxag141-B26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2174\/1874321801105010042","article-title":"The use of \u201chigh dose\u201d dexmedetomidine in a patient with critical tracheal stenosis and anterior mediastinal mass","volume":"5","author":"Voscopoulos","year":"2011","journal-title":"Open Anesth J"},{"key":"2026060813064810400_zxag141-B27","author":"Durney"},{"issue":"11","key":"2026060813064810400_zxag141-B28","doi-asserted-by":"publisher","first-page":"e0245","DOI":"10.1097\/CCE.0000000000000245","article-title":"Effects of a clonidine taper on dexmedetomidine use and withdrawal in adult critically ill patients\u2014a pilot study","volume":"2","author":"Bhatt","year":"2020","journal-title":"Crit Care Explor"},{"issue":"12","key":"2026060813064810400_zxag141-B29","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.clinthera.2024.09.006","article-title":"Evaluation of dexmedetomidine withdrawal and management after prolonged infusion","volume":"46","author":"Kim","year":"2024","journal-title":"Clin Ther"},{"key":"2026060813064810400_zxag141-B30","doi-asserted-by":"publisher","first-page":"112763","DOI":"10.1016\/j.drugalcdep.2025.112763","article-title":"Characterizing rapid changes in the prevalence and concentration of key compounds in Philadelphia\u2019s street opioid retail supply, March 2024-March 2025","volume":"274","author":"Hochstatter","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"2026060813064810400_zxag141-B31"},{"key":"2026060813064810400_zxag141-B32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ajem.2025.10.033","article-title":"Assessing the cardiac safety of a multimodal protocol for \u201ctranq dope\u201d withdrawal: a retrospective QTc analysis","volume":"99","author":"London","year":"2026","journal-title":"Am J Emerg Med"},{"issue":"1","key":"2026060813064810400_zxag141-B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13722-025-00548-z","article-title":"Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review","volume":"20","author":"Adams","year":"2025","journal-title":"Addict Sci Clin Pract"},{"key":"2026060813064810400_zxag141-B34","doi-asserted-by":"publisher","first-page":"109541","DOI":"10.1016\/j.drugalcdep.2022.109541","article-title":"Development of an intravenous low-dose buprenorphine initiation protocol","volume":"237","author":"Jablonski","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"2026060813064810400_zxag141-B35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/15563650.2025.2553811","article-title":"Transdermal buprenorphine patch-facilitated induction of sublingual buprenorphine in hospitalized patients receiving full agonist opioids: a retrospective cohort study","volume":"63","author":"Ostrowski","year":"2025","journal-title":"Clin Toxicol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag141\/68223837\/zxag141.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag141\/68223837\/zxag141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:06:55Z","timestamp":1780938415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag141\/8670084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag141","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"article-number":"zxag141"}}